Pathogen Resistance Mediated by IL-22 Signaling at the Epithelial–Microbiota Interface  by Schreiber, Fernanda et al.
ReviewFernanda Schr0022-2836/© 2015 The
(http://creativecommons.oPathogen Resistance Mediated
by IL-22 Signaling at the
Epithelial–Microbiota Interfaceeiber, Julia Maryam Arasteh and Trevor D. Lawley
Host–Microbiota Interactions Laboratory, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
Cambridge CB10 1SA, United KingdomCorrespondence to Trevor D. Lawley: tl2@sanger.ac.uk
http://dx.doi.org/10.1016/j.jmb.2015.10.013
Edited by S. CoulthurstAbstract
Intestinal colonization resistance to bacterial pathogens is generally associated, among other factors, with
mucosal homeostasis that preserves the integrity of the intestinal barrier. Mucosal homeostasis depends on
physical and molecular interactions between three components: the resident microbiota, the epithelial layer
and the local immune system. The cytokine IL-22 helps to orchestrate this three-way interaction. IL-22 is
produced by immune cells present beneath the epithelium and is induced by bacteria present in the intestine.
IL-22 stimulates the epithelial cells via the IL-22RA1–IL-10R2 receptor complex inducing changes in the
expression of genes involved in the maintenance of epithelial barrier integrity, with a variety of functions in
pathogen resistance such as mucus layer modifications and hydration, tight junction fortification and the
production of a broad range of bactericidal compounds. These mechanisms of pathogen resistance, in turn,
affect the microbiota composition and create an environment that excludes pathogens. Here we highlight the
role of IL-22 as key mediator in the give-and-take relationship between the microbiota and the host that
impacts pathogen resistance.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).The Intestinal Ecosystem Contains the
Microbiota, Epithelium and Immune Cells
The human intestinal tract is frequently challenged
with potentially virulent bacteria during eating,
drinking and environmental contamination, yet in-
fection is relatively unusual. The first obstacle an
invading pathogen would encounter when reaching
the intestinal tract is a community of commensal
bacteria, fungi, viruses and archaea collectively
known as intestinal microbiota. The intestinal micro-
biota thrives in the lumen and within and around the
nutrient-rich environment of the mucus layer in an
intimate relationship with the host, taking part in
many aspects of the host's physiology, from nutrition
to development of its immune system [1,2]. A
prospective pathogen would have to compete for
nutrients and niches with the highly adapted local
microbiota. This phenomenon is referred to as
colonization resistance and serves as a conceptual
framework for developing novel bacteria-basedAuthor. Published by Elsevier Ltd. Th
rg/licenses/by/4.0/).medicines to combat infections, as has been
shown in the case of Clostridium difficile infection
[3,4].
Acting as a filtering barrier, the mucus layer per se is
the next obstacle an invading pathogen would encoun-
ter. The composition of the mucus layer, its thickness,
its ability to exclude bacteria and its dependence on the
microbiota for its genesis, represents long-term co--
evolution between host and the commensal microbiota
[5]. The mucus layer is a physical, gel-like barrier
between the intestinal lumen and the underlying
epithelium. The mucus layer is made mainly from
Mucin-2 (MUC2), a glycoprotein secreted by epithelial
goblet cells. In the large intestine, MUC2 forms two
distinct layers. The first one, referred to as the inner
layer, is in close contact with the epithelium and is
tightly packed, virtually devoid of bacteria, partly due to
the filtering capacity of the gel but also due to the
presence of antibacterial molecules secreted by the
epithelium. The second or outer layer is loosely packed
and heavily colonized with microbiota. In contrast, theis is an open access article under the CC BY license
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Fig. 1. IL-22, a key regulator linking the microbiota, the epithelium and the immune system. An intact intestinal
epithelium is key to resistance against potential pathogens. A potential pathogen would have to compete for nutrients with
the resident microbiota, fight its way through the mucus layer and survive the chemical attack by the epithelium in the form
of antimicrobials and antibodies and avoid being detected by the underlying immune system. Maintenance of intestinal
homeostasis requires the carefully balanced interaction of three main components: the microbiota, the epithelium and the
underlying immune system. IL-22 sits at the center of this three-way interaction system, helping to maintain that balance.
The microbiota and its products are necessary for the development of IL-22-producing immune cells, such as ILC3s and
Th17 cells, and the induction of its expression. By acting on epithelial cells, IL-22 induces the expression of genes key to
the maintenance of an intact epithelial barrier, such as mucins (involved in the formation of both the mucus layer and the
glycocalyx), antimicrobials, glycoproteins (providing both a physical barrier and anchoring surface to bacteria), tight
junction proteins (keeping the epithelial cells together as an unbroken barrier) and ion channels (regulating mucosal
hydration, “flushing” potential pathogens and impairing their ability to colonize). In turn, many of these molecules will affect
the composition of the microbiota, thus closing the circle.
3677Review: Pathogen Resistance by IL-22-Microbiota Cross-talksmall intestine contains only a layer of loosely packed
mucin [6,7].
Below the mucus layers sits the epithelium, a
cellular barrier that defines the border between our
interior and the exterior, represented by the intestinal
lumen. Across the epithelium, a constant exchange
of nutrients and other molecules takes place.
Depending on the area of the intestine in question,
the epithelium is composed of several cell types with
different functions: (1) mucus-secreting goblet cells,
(2) antimicrobial-secreting Paneth cells, (3) hormo-
ne-secreting enteroendocrine cells, (4) lymphoid-as-
sociated epithelial microfold cells (M cells), (5)
nutrient-absorbing enterocytes and (6) stem cells,
which renew the intestinal epithelium every 4–
6 days [8]. With the exception of Paneth cells,
which are found solely in crypts of Lieberkuhn in
the small intestine, other cell types are found
throughout the intestinal tract at varying numbers
depending on location, with enterocytes making upthe majority of intestinal epithelium due to their role
as nutrient-absorbing cells. The majority of goblet
cells are located in the colon; individual enteroendo-
crine cells and stem cells are found throughout the
intestinal epithelium with stem cells located at the
bottom of crypts. Lymphoid-associated M cells are
found in close association with gut-associated
lymphoid tissue in both the small intestine (Payer's
patches) and colon (colonic patches) [9]. The
integrity of the epithelial barrier is maintained by
tight and gap junctions between cells that prevent
the microbiota and pathogens from invading deeper
tissues and organs. The epithelial barrier integrity
also regulates intestinal hydration through ion
trafficking: an essential factor for nutrient absorption
and clearance of potential pathogens, a process that
will be discussed later on. The epithelium also acts
as a sensor, keeping a constant surveillance on the
microbiota through the expression of innate recep-
tors, both membrane bound and cytosolic (Toll-like
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Fig. 2. IL-22 is involved in many aspects of maintenance of a healthy epithelial barrier. The development of new
techniques in recent years, like the culture of intestinal organoids, coupled with advances in RNASeq and transcriptomics,
has improved our understanding of IL-22 and its role in the intestinal epithelium. Primary murine intestinal organoids were
stimulated with IL-22 and used for transcriptomic studies (Ref. [17]). Upon exposure to IL-22, there is an increased
expression of genes related to most elements needed to keep the epithelium intact. This includes the mucus layer
(presence of antimicrobials and fucosylation of mucins; regulation of mucosal hydration), glycocalyx (important in
bacterial–epithelial cell interaction), tight and gap junctions (key to maintenance of an unbroken epithelial layer) and
engaging the underlying immune system.
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microbe-associated molecular patterns (MAMPs).
The MAMPs produced by the microbiota help
maintain a basal activation level of the local immune
system, which helps keep the microbiota at bay and
also be “primed” and ready for action in case a
pathogen manages to come in close contact to or
even breach the epithelial [10,11].
The intestinal epithelium works in close proximity
with the immune system to establish and regulate
intestinal homeostasis. Immune cells, both innate
and adaptive, accumulate beneath the epithelium in
the lamina propria and also in between epithelial
cells, constantly patrolling the area and scouting for
pathogenic invaders. One of the first responder
immune cell types are the innate lymphoid cells
(ILCs). ILCs are members of the innate immune
system but with similar functions as T cells and
include natural killer cells (NK) and ILC1, ILC2 and
ILC3. While NK cells are the innate equivalents of
cytotoxic CD8+ T cells, ILCs (ILC1, ILC2 and ILC3)
can be compared to CD4+ T helper (Th1, Th2 and
Th17) cells. What distinguishes ILCs as innate rather
than adaptive immune cells is their inability to
express antigen receptors or to undergo clonal
selection/expansion when stimulated. ILCs rapidly
respond to signals from infected or injured tissues or
as more recently discovered, the microbiota, to
produce cytokines that modulate both the innate
and adaptive immune responses. One of these
cytokines is interleukin 22 (IL-22), which has been
found to affect the expression of a wide range of
effector molecules involved in epithelial barrier
maintenance [12].
The IL-22 cytokine has emerged as a master
regulator of intestinal homeostasis and pathogenresistance by linking together and maintaining a
balanced microbiota, an intact epithelium and a
functioning immune system (Fig. 1). This review will
give an overview of IL-22 signaling at the epithelial–
microbiota interface and its role in homeostasis and
bacterial pathogen resistance.IL-22, an Epithelial-Activating Cytokine
IL-22 belongs to the IL-10 family of cytokines,
sharing a similar secondary protein structure with
other members of this family. The IL-22 receptor
complex is composed of IL-22RA1 and IL-10R2 and
initiates a signaling cascade through the activation of
STAT3 [13,14]. IL-22RA1 is the receptor component
specific for IL-22, which gives the signaling specific-
ity and restricts the action of IL-22 to epithelial cells
due to its expression pattern. Although IL-10R2 is
expressed by multiple cells types, the IL-22RA1 can
be found only on epithelial cells but not on immune
cells, therefore limiting the existence of a functional
IL-22 receptor complex to the epithelium [15].
IL-22 is produced by a variety of innate and
adaptive immune cells. These include T cells (Th1,
Th17 and Th22) and ILC3, also known as NK22 or
NKp44 cells [13,16].
Upon binding its receptor on target epithelial cells
and engaging the STAT3 signaling cascade, IL-22
induces the expression of many genes. Previous
work carried out in our laboratory, using primary
colonic organoids derived from wild-type and
IL-22RA1 knockout mice, showed differential ex-
pression of genes involved in diverse protective
functions: the epithelium and its protective mucus
layer, ion channels, antimicrobials, tight and gap
3679Review: Pathogen Resistance by IL-22-Microbiota Cross-talkjunctions and certain immune functions. All of these
elements work together in the maintenance of the
epithelial barrier (Fig. 2) [17].
When homeostasis is breached, IL-22 plays a key
role during both infection and chronic inflammation in
the gut. IL-22 is highly up-regulated during infection
with pathogens such as Citrobacter rodentium [18],
Salmonella Typhimurium [19] and C. difficile [20],
although its role is different in each case. Whereas
IL-22 has a protective function during Citrobacter
and Clostridium infections, it fails to prevent dissem-
ination and promotes colonization by Salmonella
due to increased gut inflammation.
Inflammatory bowel disease (IBD) is a chronic
inflammatory disease linked to host genetic predis-
position. For example, human genome-wide associ-
ation studies (GWAS) have identified single
nucleotide polymorphisms in the IL-22 promoter
region that are linked to IBD, implying a more
general role between IL-22 expression and the
intestinal microbiota structure [21,22]. Several
other genes linked to IBD, also identified by
GWAS, are induced by IL-22 and relate to several
aspects of maintenance of an intact epithelial barrier,
again suggesting a critical role for IL-22 both in the
homeostasis of the epithelial barrier and in the
pathogenesis of IBD [12].IL-22 Interaction with the Microbiota
The microbiota lives in a mutually beneficial
relationship with its host and its composition is
influenced by age, diet, disease, antibiotics and
genetics [23–25]. As mentioned previously, the
microbiota helps in host defense by competing with
potential pathogens for resources, but it is also
important for the correct development of the
immune system [23,26]. Indeed, there is a close
relationship between the microbiota and IL-22
production: the microbiota is required for proper
development of IL-22-producing cells, as indicated
by the reduction in the number of ILC3s in
germ-free mice [27]. During bacterial infection,
ILC3s have been shown to respond mainly to IL-1β
and IL-23 produced by myeloid cells [28,29].
Moreover, direct effects of bacterial compounds
on ILC3s have also been shown; for example,
exogenous tryptophan metabolites produced by
the microbiota act as aryl hydrocarbon receptor
agonists controlling the maintenance, survival and
function of ILC3s, including IL-22 production.
Furthermore, ILC2s and ILC3s isolated from
human tonsils produce IL-5, IL-13 and IL-22 when
stimulated with pattern recognition receptor Toll-
like receptor 2 ligands such as Pam3CYS or
Pam2CYS. When co-stimulated with IL-23, this
response was limited to ILC3s and resulted in the
production of IL-22 [30].In turn, it has been shown in mice that IL-22
expression can change the composition of microbi-
ota, regulating the expansion of segmented filamen-
tous bacteria (SFB) [31,32]. In the absence of IL-22,
the number or SFB increases. Since animals
colonized with SFB are resistant to infection by the
intestinal pathogen C. rodentium, this appears to be
detrimental for the host [33]. However, having
elevated SFB is not enough for protection, and
IL-22 expression is required to fend off Citrobacter
infection [31]. Furthermore, studies on the probiotic
effects of Bifidobacterium lactis BB12 have indicated
that this bacterium may activate ILC3 cells through
production of a low-molecular-weight peptide [34].
Other microbial metabolites such as short-chain
fatty acids (SCFAs), which are by-products of
bacterial fermentation in the large intestine, have
been shown to promote gut barrier function through
inducing the production of mucin [35]. The effect of
SCFAs on IL-22-producing ILC3 cells have not been
studied, but they may have indirect effects on these
cells by acting on leukocytes in the gastrointestinal
tract. For example, SCFAs such as butyrate have
been shown to inhibit histone deacetylases in
regulatory T cells and increase their proliferation,
which in turn may affect the activity of ILC3s [36].IL-22 Role in the Maintenance of
Epithelium Integrity
An intact epithelium consists of a continuous wall of
epithelial cells tightly adhered to each other by tight
junctions and covered by a protective mucus layer.
IL-22 regulates the expression ofmany genes involved
in the maintenance of an intact epithelium (Fig. 2).
Firstly, there is a link between IL-22 production and
the presence of a healthy mucus layer. The intestinal
mucus layer is formed by complex multimers of
secreted MUC2. Although there is no report of IL-22
regulating the production of MUC2, mice lacking
MUC2 show an increased expression of genes
belonging to the IL-22 pathway; probably, these
genes were induced due to the resulting close contact
of the microbiota with the epithelial surface [37]. The
mucus layer not only does provide a filtering
mechanism that prevents microbes to come into
close contact with the epithelium but also contains
an arsenal of antimicrobials such as RegIIIγ, β-defen-
sins and S100A proteins. The expression of these
compounds by epithelial cells and neutrophils is
regulated by, although not exclusively, IL-22, helping
control the microbiota and creating an effective
defense mechanism against pathogens.
Maintenance of mucosal hydration is a key
process in the formation of a protective barrier and
one of the primary physiological roles of epithelial
cells. When this hydration balance is broken, a
pathological state ensues as exemplified by cystic
3680 Review: Pathogen Resistance by IL-22-Microbiota Cross-talkfibrosis (decreased hydration) or cholera (increased
hydration). This water exchange occurs via chloride
channels and potentiates the role of the mucus layer
as a mechanical barrier by “flushing” the luminal
surface. This “flushing” mechanism affects the
translocation of pathogens, such as Escherichia
coli and Salmonella Typhimurium. It also causes a
shift in microbiota, affecting mostly Firmicutes and
Bacteroidetes, in particular, the genre Coprobacillus
(over-represented after “flushing”), Parasporobac-
terium and Sporobacterium (under-represented after
“flushing”) [38]. During inflammation, there is an
inhibition of Ca+-dependent chloride channels,
reducing mucosal hydration [39]. IL-22 induces the
expression of several chloride channel proteins
(CLIC5, CLCA1, CLCA2 and CLCA4), in keeping
with its anti-inflammatory role [17].
Underneath the MUC2 mucin layer and firmly
attached to the cell membrane lies the glycocalyx.
Like the mucus layer, the glycocalyx, the glycosylated
cover onepithelial cells, ismainly formedbymucins, in
this case, membrane-bound mucins (MUC1, MUC3,
MUC4, MUC12, MUC13, MUC15, MUC17 and
MUC20) [7,40]. Other glycosylated structures, like
the carcinoembryonic antigen-related cell adhesion
molecules (CEACAM), also form part of the glycoca-
lyx. The glycocalyx can have a dual role during
bacterial infection: on one hand, the glycosylated
proteins can act as recognition molecules for bacterial
pathogen adhesins (CEACAM1serves as receptor for
bothE. coli andSalmonella spp [41]) but they can also
provide a physical barrier that can protect against
infection (the presence of the glycocalyx is important
in the defense against Shigella flexneri infection [42]).
Cell surface mucins can also act as sensors, initiating
intracellular signaling cascades in response to bacte-
ria and can even act as decoy ligands, by cleaving and
releasing the extracellular domain [40]. IL-22 stimula-
tion promotes the up-regulation of several membra-
ne-boundmucins (MUC1,MUC3,MUC4,MUC13 and
MUC20), aswell as CEACAMmolecules (CEACAM1,
CEACAM2, CEACAM10 and CEACAM20), highlight-
ing its role in the maintenance of this barrier [17].
Another gene regulated by IL-22 and also related
to both mucus layer and glycocalyx is Fut2,
encoding for α(1,2)-fucosyltransferase, the enzyme
that catalyzes the addition of fucose residues to
glycoproteins. Fucosylated carbohydrates
expressed on epithelial cells are involved in gener-
ating an environmental niche for the microbiota, as
many bacteria use them for attachment and as an
energy source [43,44]. Fucose can function as
mediator between the host and the microbiota, as
signals from the microbiota are needed for fucosyla-
tion and, in turn, lack of FUT2 modifies the
composition and diversity of the microbiota [17,45].
Defective FUT2 results in susceptibility to candidi-
asis and other metabolic, infectious and inflamma-
tory diseases [46–48].Finally, tight junctions and gap junctions maintain
the intestinal barrier by keeping epithelial cells
together while at the same time regulating permeabil-
ity of ions, nutrients and water. Considering their
importance, it is not surprising that proteins involved in
the formation of tight and gap junctions have been
associated with IBD [12,49]. IL-22 can also increase
the expression of genes involved in tight and gap
junction formation (cathepsin, claudin, GJA1, GJB3,
MYO3A, GNA14 andCLECL14A), therefore playing a
role in the maintenance of an intact epithelial barrier.IL-22 Role in Modulating the
Immune Response
Activated ILC3s produce membrane-bound lym-
photoxin (LT) α1β2 and IL-22, which promote local
tissue protection and repair responses [50]. LTα1β2
activates dendritic cells, which in turn produce high
levels of IL-23 that feeds back to promote the activity
of ILC3s and the differentiation of Th17 cells [51]. It is
also worth mentioning that, in addition to LTα1β2 and
IL-22, ILC3s and Th17 cells also produce IL-17 and
GM-CSF (granulocyte-macrophage colony-stimulat-
ing factor, recently renamed Csf2) and exert other
immune modulatory effects through these pro-in-
flammatory cytokines, for example, antimicrobial
production and neutrophil recruitment [52,53]. De-
spite its lack of a direct effect on immune cells, IL-22
engages the immune system by inducing the
expression of cytokines such as IL-10 by epithelial
cells, as only epithelial cells express IL-22RA1 [54].
Moreover, IL-22 plays a dual role in controlling
inflammation on the one hand and promoting it on
the other hand. In one study, human colonic
sub-epithelial myofibroblasts were subject to a high
concentration of IL-22 (100 ng/ml) and cDNA micro-
arrays were used to identify altered gene expres-
sion. These showed an increased production of
anti-inflammatory compounds such as Follistatin and
IL-11 and the expression of pro-inflammatory IL-6
and many chemokines (CCL7, CXCL1, CXCL2,
CXCL3, CXCL6 and CXCL8) [55]. Consistent with
these results, when intestinal organoids were stim-
ulated with IL-22, a number of antimicrobials and
chemokines such as RegIIIγ, RegIIIβ, CXCL1,
CXCL3 and CXCL5 were up-regulated. Interestingly,
no cytokines were induced by IL-22 but a number of
cytokine receptors were up-regulated (IL-4RA,
IL-5RA and IL-13RA1) and IL-17RB was down-reg-
ulated [17].Conclusions
In recent years, technical advances in the fields of
microbial sequencing, transcriptomics and the cul-
ture of organoids have allowed great advances in our
3681Review: Pathogen Resistance by IL-22-Microbiota Cross-talkunderstanding of the complex relationship between
host and the microbiota. IL-22 showcases this
intimate cross-talk: produced by the host but driven
by the microbiota, it plays a key role in the
maintenance of a healthy gut, allowing both the
host and the microbiota to thrive.Acknowledgements
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